Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Chubb
Teva
Farmers Insurance
Fish and Richardson
Accenture
Moodys
UBS
US Department of Justice
Novartis

Generated: October 20, 2017

DrugPatentWatch Database Preview

Vandetanib - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for vandetanib and what is the scope of vandetanib freedom to operate?

Vandetanib
is the generic ingredient in one branded drug marketed by Genzyme Corp and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vandetanib has seventy-eight patent family members in thirty-eight countries and nine supplementary protection certificates in seven countries.

Two suppliers are listed for this compound.

Summary for Generic Name: vandetanib

US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list86
Clinical Trials: see list84
Patent Applications: see list5,261
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:vandetanib at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► SubscribeY ► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-002Apr 6, 2011RXYesYes► Subscribe► SubscribeY ► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-002Apr 6, 2011RXYesYes► Subscribe► SubscribeYY ► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► Subscribe► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-001Apr 6, 2011RXYesNo► Subscribe► SubscribeYY ► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-002Apr 6, 2011RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: vandetanib

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-001Apr 6, 2011► Subscribe► Subscribe
Genzyme Corp
CAPRELSA
vandetanib
TABLET;ORAL022405-002Apr 6, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: vandetanib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,414,148 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
6,897,210 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
6,673,803 Quinazoline derivatives and pharmaceutical compositions containing them► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: vandetanib

Country Document Number Estimated Expiration
Spain2330025► Subscribe
Switzerland0929530► Subscribe
Turkey9900674► Subscribe
World Intellectual Property Organization (WIPO)2005112934► Subscribe
Czech Republic296962► Subscribe
Japan2003238539► Subscribe
Denmark1753431► Subscribe
Japan3438818► Subscribe
South Africa9708553► Subscribe
Slovakia283175► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VANDETANIB

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2012015,C1244647Lithuania► SubscribePRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217
00543Netherlands► SubscribePRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
90028-8Sweden► SubscribePRODUCT NAME: VANDETANIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/11/749/001 20120217
0543Netherlands► SubscribePRODUCT NAME: VANDETANIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
2012000057Germany► SubscribePRODUCT NAME: VANDETANIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
12/029Ireland► SubscribePRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
C/GB12/036United Kingdom► SubscribePRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/749/001 20120217; UK EU/1/11/749/002 20120217
2012015Lithuania► SubscribePRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217
C0048France► SubscribePRODUCT NAME: VANDETANIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/11/749/002 20120217
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
Express Scripts
Mallinckrodt
Julphar
Baxter
Dow
UBS
Cerilliant
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot